A phase III clinical study (RHBH) of the treatment drug for moderate-to-severe plaque psoriasis in the Chinese population of ezizumab has achieved positive main research results

On April 23, 2021, Eli Lilly China announced that the Phase III clinical study (RHBH) evaluating ezizumab for Chinese adults with moderate to severe psoriasis has been successfully completed.

The RHBH study is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study conducted in China.

At week 12, 86.

Professor Zheng Jie from the Department of Dermatology, Ruijin Hospital Affiliated to Shanghai Jiaotong University, a major national researcher of RHBH, said: “With the launch of interleukin biologics, the majority of patients with psoriasis are expected to achieve the treatment goals of PASI 90 or even PASI 100.

Professor Zheng Jie, Department of Dermatology, Ruijin Hospital Affiliated to Shanghai Jiaotong University

In terms of onset time, in the first week, the PASI 50 response rate of the ecchizumab 80 mg Q2W group was significantly higher than that of the placebo group; and in the second week, the ecchizumab 80 mg Q2W group had a PASI 50 response rate significantly higher than that of the placebo group.

At the same time, the safety data of the RHBH study showed that echizumab was well tolerated in Chinese patients, and no new safety signals were found.

Deutsch natalizumab in 2018 was included in the list of the first batch of overseas clinical urgently needed new drugs, and in August 29, 2019 the State Drug Administration approved the Board, for the treatment of adults with moderate to severe plaque psoriasis.

Dr.